D. Przepiorka et al., ALLOGENEIC TRANSPLANTATION FOR ADVANCED LEUKEMIA - IMPROVED SHORT-TERM OUTCOME WITH BLOOD STEM-CELL GRAFTS AND TACROLIMUS, Transplantation, 62(12), 1996, pp. 1806-1810
We have evaluated the use of blood stem cell. grafts for rapid hematop
oietic recovery and tacrolimus (FK506) as GVHD prophylaxis to reduce e
arly mortality after allogeneic transplantation. Eighty-five adults wi
th advanced leukemia received high-dose thiotepa, busulfan, and cyclop
hosphamide as a preparative regimen in a prospective Phase II study, A
ll donors were HLA-matched and related, Marrow (BMT) was used for 44 p
atients and filgrastim-mobilized blood stem cells (SCT) for 41 patient
s, GVHD prophylaxis consisted of cyclosporine (CsA) or FK506: with met
hotrexate (MTX) or methylprednisolone (MP). The median time to neutrop
hil recovery was earlier after SCT than after BMT (day 10 vs, 17, P<0.
001), but this was due to the selective use of MTX only in the BMT pat
ients. The risk, of grades 2-4 GVHD was lower with FK506 than with CsA
(16% vs. 45%, P=0.02) and was the same for SCT recipients as for BMT
recipients (33% vs. 34%). Regimen-related toxicity was significantly l
ower after SCT than after BMT but did not differ between the FK506 and
CsA patients, In comparison with those receiving the standard transpl
ant (BMT with CsA and MTX), only the SCT recipients using FK506 and RP
had a significantly higher survival at day 180 posttransplant (84% vs
. 53%, P=0.014), In multivariate analyses, use of FK506 was associated
with a lower risk of treatment-related mortality and a higher surviva
l at day 180, while the diagnosis of acute lymphoblastic leukemia was
associated with a higher risk of treatment-related mortality, These da
ta suggest that the use of blood stem cell grafts and FK506 can reduce
the early mortality after allogeneic transplantation for advanced leu
kemia.